A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
NCT01403636
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
167
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Interventions
DRUG:
SAR245409
Sponsor
Sanofi